MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
复制标题
DOI：
10.1136/jitc-2020-002029
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Jianfeng Zhou
中科院分区：
文献类型：
--
作者：
Jiachen Wang;Zhen Shang;Jue Wang;Jinhuan Xu;Weigang Li;Yuqi Guan;Li Yang;Wei Zhang;Kefeng Shen;Meilan Zhang;Jin Wang;Liting Chen;Qinlu Li;Cheng He;Na Wang;Liang Huang;Yi Xiao;Min Xiao;Jianfeng Zhou
High-grade B cell lymphoma with MYC, BCL2, and BCL6 rearrangements (HGBL-TH) is rare and often portends poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR) T cell therapy is a new paradigm for the treatment of refractory/relapsed (r/r) lymphomas, but its therapeutic effects in treating HGBLTH remain inconclusive. Here, we report a patient with HGBL-TH who failed to achieve complete remission (CR) and progressed rapidly after first-line and second-line therapies. Furthermore, he was resistant to the CAR19 and CAR22 T cell cocktail therapy following autologous hematopoietic stem cell transplantation (ASCT), and disease progressed again after the anti-B cell maturation antigen (BCMA) CAR T cell immunotherapy. Comprehensive analyses were performed to explore the inherent mechanism for resistance, which indicated that tumorderived antigen escape, clonal evolution, and T cell defects were involved in it. This is the first report of an HGBL-TH patient with TP53 deletion and additional germline (PIM1) and somatic mutations (TP53, KMT2D, and IGLL5) who was treated with ASCT, CD19/22 CAR T cell cocktail therapy and BCMA CAR T cell immunotherapy. The clinical evolution and genetic features of this case may help to explain the underlying mechanism of treatment resistance and provide novel insights into lymphoma
